REGENXBIO and Solid Biosciences Take Aim at Rare Diseases with AAV Gene Therapies via New Pathway Development Consortium

Published on :

Rare disease specialist REGENXBIO is partnering with Solid Biosciences to advance AAV gene therapies for rare diseases through an accelerated approval pathway with the U.S. Food and Drug Administration.